Experimental HCV Drugs
Experimental HCV Drugs
CROI 2014: Short 6-Week Oral Treatment Works for Most Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 04 March 2014 00:00
- Written by Liz Highleyman
Interferon- and ribavirin-free treatment using sofosbuvir, ledipasvir, and a third drug for as little as 6 weeks can cure a majority of previously untreated people with genotype 1 hepatitis C, including those with traditional predictors of poor response, according to results from the SYNERGY trial presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.
CROI 2014: Faldaprevir + Interferon Cures HIV/HCV Coinfected People
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 04 March 2014 00:00
- Written by Liz Highleyman
The hepatitis C virus (HCV) protease inhibitor faldaprevir added to pegylated interferon and ribavirin cured nearly three-quarters of genotype 1 HIV/HCV coinfected patients in the STARTVerso4 trial, equaling response rates for people with HCV alone, according to a report this week at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston.
CROI 2014: Retrovirus Conference Now Underway in Boston
- Details
- Category: HIV Treatment
- Published on Monday, 03 March 2014 00:00
- Written by Liz Highleyman
The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) kicked off in Boston this week with a program for young investigators, a press conference on new hepatitis C treatments, and opening lectures on HIV immune response and cross-species transmission and an update on the epidemic in West Africa.
HIVandHepatitis.com will be on site all week bringing you the latest news.
CROI 2014: Sofosbuvir + Ribavirin Cures 75% of Genotype 1 HIV/HCV Coinfected Patients
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 04 March 2014 00:00
- Written by Liz Highleyman
An interferon-free regimen of sofosbuvir plus ribavirin for 24 weeks led to sustained response in three-quarters of previously untreated genotype 1 HIV/HCV coinfected patients in the PHOTON-1 study, but a shorter 12-week regimen did not work as well for people with hepatitis C virus genotype 3, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.
CROI 2014: The Role of Interferon in HIV Response [VIDEO]
- Details
- Category: HIV Treatment
- Published on Monday, 03 March 2014 00:00
- Written by Gregory Fowler
Although interferon is on its way out as a standard of care for hepatitis C, researchers are learning more about its role in HIV, conference vice chair Julie Overbaugh said at a media briefing on the opening day of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.
Web Design and Development by